Correlation Between Neovacs SA and Sartorius Stedim

Can any of the company-specific risk be diversified away by investing in both Neovacs SA and Sartorius Stedim at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neovacs SA and Sartorius Stedim into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Neovacs SA and Sartorius Stedim Biotech, you can compare the effects of market volatilities on Neovacs SA and Sartorius Stedim and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neovacs SA with a short position of Sartorius Stedim. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neovacs SA and Sartorius Stedim.

Diversification Opportunities for Neovacs SA and Sartorius Stedim

-0.77

Correlation Coefficient

Neovacs SA  Sartorius Stedim

Pay attention - limited upside

The 3 months correlation between Neovacs and Sartorius is -0.77. Overlapping area represents the amount of risk that can be diversified away by holding Neovacs SA and Sartorius Stedim Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sartorius Stedim Biotech and Neovacs SA is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neovacs SA are associated (or correlated) with Sartorius Stedim. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sartorius Stedim Biotech has no effect on the direction of Neovacs SA i.e., Neovacs SA and Sartorius Stedim go up and down completely randomly.

Pair Corralation between Neovacs SA and Sartorius Stedim

Assuming the 90 days trading horizon Neovacs SA is expected to under-perform the Sartorius Stedim. In addition to that, Neovacs SA is 5.74 times more volatile than Sartorius Stedim Biotech. It trades about -0.47 of its total potential returns per unit of risk. Sartorius Stedim Biotech is currently generating about 0.09 per unit of volatility. If you would invest  18,510  in Sartorius Stedim Biotech on December 2, 2024 and sell it today you would earn a total of  1,390  from holding Sartorius Stedim Biotech or generate 7.51% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Neovacs SA  vs.  Sartorius Stedim Biotech

Neovacs SA

Risk-Adjusted Performance

Very Weak

Over the last 90 days Neovacs SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Sartorius Stedim Biotech

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Sartorius Stedim Biotech are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak primary indicators, Sartorius Stedim may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with Neovacs SA and Sartorius Stedim

The main advantage of trading using opposite Neovacs SA and Sartorius Stedim positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neovacs SA position performs unexpectedly, Sartorius Stedim can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sartorius Stedim will offset losses from the drop in Sartorius Stedim's long position.

The idea behind Neovacs SA and Sartorius Stedim Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.